The effects of thymoquinone and doxorubicin on leukemia and cardiomyocyte cell lines

51st Annual Rocky Mountain Bioengineering Symposium, RMBS 2014 and 51st International ISA Biomedical Sciences Instrumentation Symposium 2014

Volumn , Issue , 2014, Pages 391-396

  Brown, R Keith ^a   Wilson, Gerri ^a   Tucci, Michelle ^a   Benghuzzi, Hamed ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Cardiac myocyte; Doxorubicin; Thymoquinone leukemia

Indexed keywords

CELL CULTURE; CELL DEATH; CELL MEMBRANES; CELLULAR MANUFACTURING; HEART; MORPHOLOGY;

ACUTE LYMPHOBLASTIC LEUKEMIA; CARDIAC MYOCYTES; CHEMOTHERAPEUTIC AGENTS; COMBINATION TREATMENTS; CONGESTIVE HEART FAILURES; DOXORUBICIN; MORPHOLOGICAL CHANGES; THYMOQUINONE;

DISEASES;

EID: 84904913835     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (41)

1. S. Hunger, Acute Lymphoblastic Leukemia, New York: Springer, 2014, pp. 225-238.
2. L. Ries, Cancer incidence and survival amoung children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute, 1999.
3. A. A. C. W. e. a. Gaynon PS, "Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report," Leukemia, vol. 24, no. 2, pp. 285-297, 2010.
4. H. M. Hardip S., "Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury," Clinical Science, vol. 126, no. 6, p. 377, 2014.
5. T. J. R. L. e. Tangka F., "Cancer treatment cost in the United States: Has the burden shifted over time?," Cancer, vol. 116, no. 14, pp. 3477-3484, 2010.
6. L. J. K. D. M. A. Yabroff K., "EconomicBurden of Cancer in the United States: Estimates, Projections, and Future Research," Cancer Epidemilogy,Biomarkers and Preverntion, vol. 20, pp. 1996-2005, 2011.
7. Y. K. S. Y. e. Mariotto A., "Projections of the cost of cancer in the United States: 2010-2020," Journal of the National Cancer Institute. vol. 103, no. 2, pp. 117-128, 2011.
8. G. D. I. S. K. e. a. Levitt, "Does anthracycline administration by infusion in children affect late cardiotoxicity?," British Journal of Haematology, vol. 124, no. 4, p. 463-468, 2004.
9. v. d. B. H. R. M. e. van Dalena E., "Should anthracyclines and dexrazoxane be used for children with cancer?," The Lancet Oncology, vol. 12, no. 1, 2011.
10. S. A. B. A. S. P. Ludke A., "Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes," Molecullar and Cellular Biochemistry, vol. 360, no. 1-2, pp. 215-224, 2012.
11. T. P. M. P. Bristow M., "Early Anthracycline Toxicity," American Journal of Medicine, vol. 85, pp. 823-828, 1979.
12. S. L. S. S. S. e. a. Lipshultz, "Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia," Journal of Clinical Oncology, vol. 23, no. 12, pp. 2629-2636, 2005.
13. L. T. Vander Heide R., "Molecular basis of anthracycline-induced cardiotoxicity," Heart and Metabolism, vol. 35, pp. 1-4. 2007.
14. v. d. P. H. K. e. Van Dalen E., "Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study," European Journal of Cancer, vol. 42, pp. 3191-3198, 2006.
15. Z. J. H. N. e. Chatterjee K., "Dixorubicin cardiomypathy," Cardiology, vol. 115, pp. 115-162, 2010.
16. I. W. C. M. e. Nithipongvanitch R., "Mitochondrial and nuclear p53 localization in cardiomycytes: Redox modulation by doxorubicin (Adriamycin)?," Antioxidants & Redox Signaling, vol. 7, 2007.
17. X. Y. Z. J. e. a. Polyak K., "A model for p53-induced apotosis," Nature, vol. 389, pp. 300-305, 1997.
18. C. M. S. C. D. e. a. Chaiswing L., "Oxidative damage precedes nitrative damage in Adramycin-induced cardiac mitochondrial injury," Toxicologic Pathology, vol. 32, pp. 536-547, 2004.
19. Z. L. R. S. e. Chen B., "Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: Implications for anthracycline cardiomyopathy," PlosOne, vol. 7, no. 4, p. e35743, 2012.
20. K. D. D. I. I. N. Singal P., "Adramycin-induced heart failure: mechanism and modulation," Molecullar and Cellular Biochemistry. vol. 207, pp. 77-86, 2000.
21. L. S. M. S. a. Lipsshultz S., "Anthrcycline associated cardiotoxicity in survivors of childhood cancers," Heart, vol. 94, no. 4, pp. 525-533, 2008.
22. S. P. T. C. Steinherz L., "Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients," Medical and Pediatric Oncology, vol. 24, no. 6, pp. 352-361, 1995.
23. B. A. Weseler A., "Oxidative stress and vascular function: implications for pharmacologic treatments," Current Hypertensive Reports, vol. 12, pp. 154-161, 2010.
24. P. X. C. B. e. a. Sawyer D., "Mechanisms of anthracycline cardiac injury: Can we idetify stratagies for cardioprotection?," Progress in Cardiovascular Disease, vol. 53, pp. 105-113, 2010.
25. A. A. R. M. S. N. Al-Ali J., "Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats," Journal of Ayub Medical College, vol. 20, no. 2, pp. 25-27, 2008.
26. B. S. A. A. e. Padhye S., "From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond," Cancer Therapy, vol. 6, no. b, pp. 495-510, 2008.
27. N. H. S. B. e. a. Ravindran J., "Thymoquinone Poly(lactide-co- glycolide) Nanoparticles Exhibit Enhanced Anti-proliferative, Anti-inflammatory, and Chemosensitization Potential," Biochemical Pharmacology, vol. 79, no. 11, pp. 1640-1647, 2010.
28. A. A.-A. A. K. H. e. a. Ashour, "Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis," Molecular and Cellular Biochemistry, 2014.
29. M. M. Nagi M., "Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanisim of protection," Pharmacological Reasearch, vol. 41, no. 3, pp. 283-289, 2000.
30. J. N. L. G. S. M. A. D. L. Yeh, "A Model-Based Estimate of Cumulative Excess Mortality in Survivors of Childhood Cancer," Annals of Internal Medicine, vol. 152, no. 7, pp. 409-417, 6 April 2010.
31. D. C. A. G. C. N. C. M. G. G. R. M. V. F. F. C. C. C. Cardinale, "Anthracycline-Induced Cardiomyopathy : Clinical Relevance and Response to Pharmacologic Therapy," Cardiology, vol. 53, no. 3, pp. 213-220, 19 Jan 2010.
32. L. C. H. Kremer, "Anthracycline cardiotoxicity in children," New England Journal of Medicine, vol. 351, pp. 120-121, 2004.
33. S. D. S. H. R. Hancock, "Cardiac disease following treatment of Hodgkin's disease in children and adolescents.," Journal of Clinical Oncology, vol. 11, no. 7, pp. 1208-1215, July 1993.
34. M. S. I. M. W.-B.-A. Y. B. a. A. L. Friedberg, "Cardiac Function in Long-Term Survivors of Childhood Lymphoma," Cardiology Research and Practice, p. 8, 20 Jan 2011.
35. D. P. X. C. B. P. L. L. C. Sawyer, "Mechanisms of anthracycline cardiac injury: Can we idetify stratagies for cardioprotection?," Progress in Cardiovascular Disease, vol. 53, pp. 105-113, 2010.
36. R. S. O. P. A. P. M. Franco, "The central role of glutathione in the pathophysiology of human diseases," Archives of Physiology and Biochemistry, vol. 113, pp. 234-258, 2007.
37. Y. L. I. S. H. K. H. K. Y. Ko, "Mechanism of gltathione depletion simulated ischemia-reperfusion of H9c2 cardiac myocytes," Free Radical Research, vol. 45, pp. 1074-1082, 2011.
38. A. A. D. G. O. T. M. Mohammed, "Thymoquinone inhibits the activation of Nf-kB in brain and spinal cord of experimental autoimmune encephalomyelitis," Biomedical Sciences Instrumentation, vol. 41, pp. 388-393, 2005.
39. R. T. M. B. H. Wilkins, "Evaluation of raw 264.7 macrophages treated with epigallocatechin-3-gallate and thymoquinone," Biomedical Sciences Instrumentation, vol. 45, pp. 346-351, 2009.
40. M. a.-S. O. H. M. S.-A. M. Nagi, "Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats," Journal of Biochemical Molecular Toxicology, vol. 25, no. 3, pp. 135-142, 2011.
41. K. S. R. Effenberger-Neidnicht, "Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin," Cancer Chemotharapy and Pharmacology, vol. 67, no. 4, pp. 867-874, 2011.